TSX runs higher on rate cut expectations
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $678.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN), currently valued at $58.77 billion with a P/E ratio of 13.2, ahead of the company’s second-quarter earnings report scheduled for Friday. InvestingPro analysis indicates the stock is currently trading below its Fair Value.
The firm’s analysis follows Sanofi (NASDAQ:SNY)’s Q2 results released Thursday, which provided insight into sales performance of Dupixent, the drug partnered with Regeneron. Dupixent sales showed a moderate beat compared to consensus estimates worldwide and in the U.S. market, with a slight miss in regions outside the United States when measured in euros.
The overall performance indicates a U.S. dollar beat versus Regeneron consensus estimates, driven primarily by COPD (chronic obstructive pulmonary disease) sales and favorable foreign exchange conditions. Cantor Fitzgerald noted the euro-to-dollar exchange rate stood at 1.13 in Q2 2025, compared to 1.05 in the first quarter.
Dupixent’s early launch in the COPD indication is tracking above Street expectations, confirming Cantor Fitzgerald’s earlier projections about the drug’s market penetration in this new treatment area.
The research firm believes Dupixent’s growth trajectory remains strong, citing the early stage of its COPD launch, and reaffirmed its fiscal year 2025 outlook for Regeneron, which stands above current consensus estimates. The company’s strong balance sheet and cash flows support its growth initiatives, with analyst targets ranging from $504 to $940 per share.
In other recent news, Regeneron Pharmaceuticals has been the focus of several significant developments. UBS raised its price target for Regeneron to $584, citing expectations that the company’s Eylea franchise will surpass consensus revenue estimates in the second quarter of 2025. Meanwhile, Bernstein reiterated an Outperform rating with a $750 price target, following positive Phase 2 data from Apogee (NASDAQ:APOG)’s IL-13 inhibitor, APG777, for atopic dermatitis. JPMorgan maintained its Overweight rating and $800 price target ahead of Regeneron’s upcoming second-quarter earnings, predicting Eylea sales of $729 million in the U.S., slightly above consensus estimates. Additionally, TD Cowen reiterated a Buy rating and $800 price target after the FDA approved Regeneron’s multiple myeloma treatment, Lynozyfic. The FDA’s accelerated approval of Lynozyfic for blood cancer therapy was based on favorable trial results, marking it as the third BCMAxCD3 therapy approved for this condition. These recent developments highlight the company’s ongoing advancements in both its product pipeline and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.